Skip to content
Text “Loti” to 833-962-6682 to join the Loti Labs VIP Group!
Loti Labs Resources Research Liquids

Ipamorelin vs GHRP-6 (and GHRP-2): Published Hormone Release Data Compared

Published GH release measurements, ACTH, cortisol and prolactin measurements in swine, available pharmacokinetic and time course data, desensitization studies in rats and receptor pharmacology are summarised for ipamorelin, GHRP-6 and GHRP-2.

Published GH release measurements, ACTH, cortisol and prolactin measurements in swine, available pharmacokinetic and time course data, desensitization studies in rats and receptor pharmacology are summarised for ipamorelin, GHRP-6 and GHRP-2.

Ipamorelin and GHRP-6 had similar EC50 values for GH release in rat pituitary cells: 1.3 and 2.2 nmol/L, respectively [1]. This comparison adds GHRP-2 and looks at peptide structure, receptor pharmacology, swine endocrine measurements and rodent feeding observations. The primary papers are linked below; their endpoints and experimental models differ.

Key findings

  • In rat pituitary cell cultures, the GH release EC50 was 1.3 nmol/L for ipamorelin and 2.2 nmol/L for GHRP-6, which the authors described as similar potency [1].
  • In conscious swine, GHRP-6 and GHRP-2 raised plasma ACTH and cortisol, whereas ipamorelin gave ACTH and cortisol levels that did not differ significantly from those after GHRH, including at experimental quantities more than 200 times its ED50 for GH release [1].
  • In sated adult male rats, GHRP-6 delivered into the lateral cerebral ventricles was followed by eating, with the proportion of eating animals rising across the experimental range. The change in plasma GH was not related to the amount of peptide [2].
  • In a study of healthy male volunteers, the terminal half-life of ipamorelin was about 2 hours [3]. This is a published human pharmacokinetic result, not an animal value or a recommendation for use.
  • In transgenic growth retarded rats, continuous and pulsatile GHRP-6 infusion produced different growth and GH response patterns [4].

Receptor pharmacology and historical context

The growth hormone secretagogue receptor, GHS-R1a, is also called the ghrelin receptor. The receptor was cloned in 1996 [5], about twelve years after the 1984 report of GHRP-6 [6]. Ghrelin, its natural ligand, was purified from rat stomach and reported in 1999. It is a 28 amino acid peptide with n-octanoylation at serine 3 [7].

The ipamorelin evidence in Raun’s study was functional: GHRP and GHRH antagonists indicated a GHRP-like receptor rather than the GHRH receptor [1]. Howard and colleagues cloned a receptor from pituitary and hypothalamic tissue [5]. These observations should not be presented as a side by side receptor binding experiment involving all three peptides.

The studies below measured GH release, other endocrine readouts and feeding behavior in specific experimental models. Those endpoints answer different questions. They are not interchangeable measures of receptor binding selectivity.

Five residues versus six

GHRP-6 has the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Its development began with the observation that D-Trp2 and D-Phe2 analogs of methionine enkephalin amide released GH weakly from rat pituitary tissue in vitro. This guided the design of more active GH-releasing peptides [8].

By 1984, the group had described a hexapeptide with GH release in vitro and in animals that increased across the experimental range, without concomitant release of LH, FSH, TSH or prolactin. It was active in rats, monkeys, lambs and calves, and in chicks under special conditions [6].

GHRP-2 also has six residues: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 [14]. It differs from GHRP-6 at position 1, where D-Ala replaces His, and at position 2, where D-2-naphthylalanine replaces D-Trp. A separate human study described GHRP-2 and hexarelin as synthetic analogs of GHRP-6 [9]. That human paper is not the source of the swine comparison.

Ipamorelin is shorter. It is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, in which Aib is 2-aminoisobutyric acid and D-2-Nal is D-2-naphthylalanine. It was identified in a series of compounds lacking the central Ala-Trp pair of GHRP-1 [1]. Aib at position 1 and D-2-Nal at position 3 are non-proteinogenic building blocks. The sequence also contains D-Phe.

Each of the three peptides contains D-amino acids. Their sequences alone do not establish a quantitative stability ranking. A direct rat pharmacokinetic comparison found that ipamorelin had systemic plasma clearance about fivefold lower than GHRP-6 [10].

Potency in cell and animal experiments

Raun and colleagues compared ipamorelin with GHRP-6 in rat pituitary cells, anesthetized rats and conscious swine, and included GHRP-2 in the swine experiments [1]. The results depended on both the model and the endpoint.

In rat pituitary cells, ipamorelin’s GH release EC50 was 1.3 nmol/L and GHRP-6’s was 2.2 nmol/L. Ipamorelin’s maximal response was about 85% of the GHRP-6 response [1]. These are functional hormone release measurements, not binding affinity values.

In anesthetized rats, the GH release ED50 was 80 nmol/kg for ipamorelin and 115 nmol/kg for GHRP-6. Maximal GH concentrations were 1,545 and 1,167 ng/mL, respectively [1]. These historical animal exposure values identify the comparison; they are not instructions for use.

In conscious swine, GH release ED50 values were 0.6 nmol/kg for GHRP-2, 2.3 nmol/kg for ipamorelin and 3.9 nmol/kg for GHRP-6 [1].

In that swine experiment, GHRP-2 had the lowest ED50, but its maximal GH concentration was 56 ng/mL, compared with 65 for ipamorelin and 74 for GHRP-6 [1]. A lower ED50 indicates greater potency in that assay. It does not imply a higher maximal response. Here the two rankings differed.

No ranking of receptor binding affinity is made here, because this comparison measured hormone release rather than side by side binding of all three peptides [1].

Endocrine measurements in swine

ACTH and cortisol

In swine, none of the three peptides altered plasma FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 both raised plasma ACTH and cortisol. Ipamorelin did not produce ACTH or cortisol levels significantly different from those after GHRH stimulation, including at experimental quantities more than 200 times its ED50 for GH release [1].

The authors presented ipamorelin as a GHRP receptor agonist with GH release selectivity similar to that of GHRH [1]. That conclusion concerned the hormone panel and conditions they tested.

Limits of the hormone comparisons

The swine measurements did not establish why these peptides produced different ACTH and cortisol responses [1]. The comparison applies to swine and to the experimental conditions used. It does not establish a general selectivity ranking across species or show that ACTH and cortisol can never change with ipamorelin.

The data also did not support calling GHRP-2 more selective than GHRP-6 on the basis of ACTH and cortisol. Endocrine concentrations and receptor binding selectivity are different endpoints.

GHRP-6 and CD36

GHRP-6 has affinity for CD36, a scavenger receptor distinct from GHS-R1a [11]. Proulx and colleagues examined azapeptide analogs of GHRP-6. Replacing residues at certain positions with aza-amino acids reduced GHS-R1a affinity by at least a factor of 100; some analogs retained CD36 affinity [11].

Selected analogs also reduced microvascular sprouting in a choroid explant assay [11]. These analogs are distinct compounds, not interchangeable controls or evidence that unmodified GHRP-6 produced the same result. The paper does not establish that ipamorelin or GHRP-2 has no other targets.

Feeding observations in rats

In sated adult male rats, delivery of GHRP-6 into the lateral cerebral ventricles was followed by eating. The proportion of animals that ate rose across the experimental range, with a statistically significant relationship (p < 0.01). The change in plasma GH over the following hour was not related to the amount of peptide [2]. This is narrower than saying GH did not change.

In another rat study, intracerebroventricular ghrelin or GHRP-6 stimulated food intake, and pretreatment with a Y1 NPY receptor antagonist blocked the feeding response to both peptides. Both induced c-Fos in several hypothalamic regions, including the arcuate and paraventricular nuclei, and in two brainstem regions, the nucleus of the solitary tract and the area postrema. After GHRP-6, orexin containing neurons of the lateral hypothalamus were also activated. The GHRP-6 c-Fos pattern was unchanged when food was withheld [12].

The studies cited here include no matched feeding comparison of ipamorelin and GHRP-6, so their relative feeding effects are not established [2,12]. The central route used in these rat experiments is also part of their interpretation.

Half-life and time course

Gobburu’s pharmacokinetic analysis involved healthy male volunteers, with eight subjects at each experimental level. It reported a terminal ipamorelin half-life of roughly 2 hours, clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg. The parameters showed proportionality over the range examined [3]. These are human literature measurements, not values that can be silently transferred to rats or other species.

In rats, GH rose within 2 minutes of GHRP-6 exposure, peaked at 10 to 20 minutes and usually returned to baseline by 2 hours [6]. That is a GH response profile, not the plasma half-life of the peptide itself.

Johansen and colleagues directly compared the pharmacokinetics of ipamorelin, GHRP-2 and GHRP-6, along with two other peptides, in male rats [10]. Plasma concentrations declined biexponentially. Ipamorelin had about fivefold lower systemic clearance than GHRP-6 and was mainly excreted in urine, whereas GHRP-6 was predominantly excreted in bile. Exact GHRP-2 half-life values are not included in this comparison.

Desensitization in rat experiments

In transgenic growth retarded rats, continuous GHRP-6 infusion produced only a transient growth response, together with weaker GH and corticosterone responses to a later GHRP-6 challenge. Arcuate GHS-R mRNA did not fall, whereas periventricular somatostatin mRNA rose. Pulsatile infusion sustained growth and GH responses; corticosterone responses were also suppressed with pulsatile exposure [4].

The authors proposed that raised somatostatin expression may account for the weaker responses during continuous infusion. The mRNA measurements do not by themselves exclude changes at the level of receptor protein or signaling [4]. Describing the result as proof against receptor desensitization would go beyond the data.

In Bowers’ 1984 study, immature rats exposed repeatedly to GHRP-6 gained more weight than controls, and their pituitaries remained responsive at the study endpoint [6]. We did not find a matched comparison establishing whether ipamorelin, GHRP-2 and GHRP-6 differed in desensitization under the same experimental conditions.

Findings with GHRH

GHRH and the peptides discussed here act through distinct receptor systems, as indicated by antagonist profiling of ipamorelin [1] and by the receptor cloning work [5]. A human study reported synergistic GH release when GHRP-6 and GHRH were combined [13]. This is a historical pharmacological observation, not a recommendation for combined use.

In transgenic growth retarded rats, Wells and Houston observed greater skeletal growth and lower pituitary GH stores with combined GRF and GHRP-6 exposure than with GHRP-6 alone [4]. The depletion of pituitary stores was a limitation, and the authors questioned whether the growth rate could be sustained.

Side by side

Parameter Ipamorelin GHRP-6 GHRP-2
Structure Pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2 [1] Hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 [6] Hexapeptide, D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 [14]
Rat pituitary GH release EC50 1.3 nmol/L [1] 2.2 nmol/L [1] No value reproduced here
Conscious swine ED50; maximal GH 2.3 nmol/kg; 65 ng/mL [1] 3.9 nmol/kg; 74 ng/mL [1] 0.6 nmol/kg; 56 ng/mL [1]
ACTH and cortisol in swine Not significantly different from GHRH, including above 200 times the GH release ED50 [1] Increased [1] Increased [1]
Prolactin in swine Unchanged [1] Unchanged [1] Unchanged [1]
Feeding in rats No matched comparison in the cited sources Increased incidence of eating after central exposure; Y1 NPY antagonism blocked feeding in a separate study [2,12] No matched comparison in the cited sources
CD36 Not established by these sources Affinity reported; selected aza-analogs retained CD36 affinity with reduced GHS-R1a affinity [11] Not established by these sources
Pharmacokinetic context Human terminal half-life about 2 hours [3] A rat GH response returning to baseline by about 2 hours is not a peptide half-life [6] Exact rat half-life not established here [10]

Frequently asked questions

What is the difference between ipamorelin and GHRP-6?

Ipamorelin is a pentapeptide, while GHRP-6 is a hexapeptide. Their GH release EC50 values were similar in rat pituitary cells. In swine, ACTH and cortisol increased with GHRP-6, while ipamorelin’s measurements did not differ significantly from the GHRH comparison [1].

How did GHRP-2 and GHRP-6 compare in swine?

In conscious swine, GHRP-2 had a lower ED50 (0.6 vs 3.9 nmol/kg) but a lower maximal GH response (56 vs 74 ng/mL) [1]. It was more potent but had a lower maximal measured response in that model.

What did the swine study report for ipamorelin’s cortisol and prolactin measurements?

Prolactin was unchanged for all three peptides. Ipamorelin’s ACTH and cortisol measurements did not differ significantly from the GHRH comparison [1]. This does not establish an absence of effects in every model.

What evidence connected GHRP-6 with feeding in rats?

An NPY Y1 antagonist blocked the feeding response associated with central GHRP-6 exposure. The cited work also reported c-Fos staining in hypothalamic and brainstem regions [12].

References

  1. Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. DOI: 10.1530/eje.0.1390552. PMID 9849822.
  2. Locke W, et al. Life Sci. 1995;56(16):1347-1352. DOI: 10.1016/0024-3205(95)00087-9. PMID 8614257.
  3. Gobburu JV, et al. Pharm Res. 1999;16(9):1412-1416. DOI: 10.1023/A:1018955126402. PMID 10496658.
  4. Wells T, Houston PA. J Neuroendocrinol. 2001;13(6):496-504. DOI: 10.1046/j.1365-2826.2001.00661.x. PMID 11412336.
  5. Howard AD, et al. Science. 1996;273(5277):974-977. DOI: 10.1126/science.273.5277.974. PMID 8688086.
  6. Bowers CY, et al. Endocrinology. 1984;114(5):1537-1545. DOI: 10.1210/endo-114-5-1537. PMID 6714155.
  7. Kojima M, et al. Nature. 1999;402(6762):656-660. DOI: 10.1038/45230. PMID 10604470.
  8. Momany FA, et al. Endocrinology. 1981;108(1):31-39. DOI: 10.1210/endo-108-1-31. PMID 6109621.
  9. Arvat E, et al. Peptides. 1997;18(6):885-891. DOI: 10.1016/S0196-9781(97)00016-8. PMID 9285939.
  10. Johansen PB, et al. Xenobiotica. 1998;28(11):1083-1092. DOI: 10.1080/004982598238976. PMID 9879640.
  11. Proulx C, et al. J Med Chem. 2012;55(14):6502-6511. DOI: 10.1021/jm300557t. PMID 22712585.
  12. Lawrence CB, et al. Endocrinology. 2002;143(1):155-162. DOI: 10.1210/endo.143.1.8561. PMID 11751604.
  13. Bowers CY, et al. J Clin Endocrinol Metab. 1990;70(4):975-982. DOI: 10.1210/jcem-70-4-975. PMID 2108187.
  14. Okano M, et al. Rapid Commun Mass Spectrom. 2010;24(14):2046-2056. DOI: 10.1002/rcm.4619. PMID 20552695.

This content is intended for research purposes only and is not meant to constitute medical advice. Not for human or veterinary use.

Research-use notice

This educational material discusses laboratory research concepts only. Loti Labs products are intended strictly for research and development use and are not for human consumption.

Ready to explore?

Browse high-purity research materials by format or view the full catalog.